MX2013000333A - N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. - Google Patents

N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.

Info

Publication number
MX2013000333A
MX2013000333A MX2013000333A MX2013000333A MX2013000333A MX 2013000333 A MX2013000333 A MX 2013000333A MX 2013000333 A MX2013000333 A MX 2013000333A MX 2013000333 A MX2013000333 A MX 2013000333A MX 2013000333 A MX2013000333 A MX 2013000333A
Authority
MX
Mexico
Prior art keywords
laquinimod
deuterium
enriched
compound
pharmaceutically acceptable
Prior art date
Application number
MX2013000333A
Other languages
English (en)
Spanish (es)
Inventor
Avital Laxer
Victor Piryatinsky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45439026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013000333(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2013000333A publication Critical patent/MX2013000333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
MX2013000333A 2010-07-09 2011-07-08 N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. MX2013000333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39929710P 2010-07-09 2010-07-09
PCT/US2011/043383 WO2012006538A1 (en) 2010-07-09 2011-07-08 Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

Publications (1)

Publication Number Publication Date
MX2013000333A true MX2013000333A (es) 2013-02-26

Family

ID=45439026

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000333A MX2013000333A (es) 2010-07-09 2011-07-08 N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.

Country Status (20)

Country Link
US (3) US8580819B2 (enExample)
EP (2) EP3213636A1 (enExample)
JP (2) JP2013535437A (enExample)
KR (1) KR20130092558A (enExample)
CN (2) CN104610144A (enExample)
AR (1) AR082150A1 (enExample)
AU (1) AU2011274496B2 (enExample)
BR (1) BR112013000599A2 (enExample)
CA (1) CA2804986A1 (enExample)
CL (1) CL2013000063A1 (enExample)
EA (1) EA025377B1 (enExample)
IL (1) IL251600A0 (enExample)
MX (1) MX2013000333A (enExample)
NZ (1) NZ606587A (enExample)
PE (1) PE20130396A1 (enExample)
PH (1) PH12013500065A1 (enExample)
SG (2) SG10201505236YA (enExample)
UY (1) UY33504A (enExample)
WO (1) WO2012006538A1 (enExample)
ZA (1) ZA201300956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937642B1 (en) * 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
BRPI0713694A2 (pt) 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CN107308162A (zh) * 2009-06-19 2017-11-03 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
NZ602510A (en) * 2010-03-03 2014-11-28 Teva Pharma Treatment of lupus nephritis using laquinimod
SG183513A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
NZ602512A (en) * 2010-03-03 2014-07-25 Teva Pharma Treatment of lupus arthritis using laquinimod
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1212936A1 (zh) 2012-11-07 2016-06-24 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
CN103848785B (zh) * 2012-12-04 2016-07-13 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
CN103145562B (zh) * 2013-03-18 2015-06-17 黄河三角洲京博化工研究院有限公司 一种n-乙基苯胺的制备方法
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
JP6762507B2 (ja) * 2015-03-20 2020-09-30 ギャバ セラピューティクス、インコーポレイテッド エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用
EP4024330B1 (en) * 2019-08-28 2023-08-09 NISSAN MOTOR Co., Ltd. Object recognition method and object recognition device
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
MX2022006439A (es) * 2019-12-19 2022-07-19 Active Biotech Ab Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva.
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SI1187601T1 (sl) 1999-06-07 2005-12-31 Altana Pharma Ag Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1937642B1 (en) * 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
BRPI0713694A2 (pt) 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
CN101687824A (zh) 2007-04-19 2010-03-31 康塞特医药品公司 氘化吗啉基化合物
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
AU2009288108B2 (en) * 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
CN107308162A (zh) 2009-06-19 2017-11-03 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化
RS54707B1 (sr) 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
SG183513A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
NZ602512A (en) 2010-03-03 2014-07-25 Teva Pharma Treatment of lupus arthritis using laquinimod
NZ602510A (en) 2010-03-03 2014-11-28 Teva Pharma Treatment of lupus nephritis using laquinimod
BR112013000607A2 (pt) 2010-07-09 2016-06-28 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
UA111959C2 (uk) 2010-12-07 2016-07-11 Тева Фармасьютікл Індастріз Лтд. Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом

Also Published As

Publication number Publication date
ZA201300956B (en) 2014-04-30
EA025377B1 (ru) 2016-12-30
US20140051723A1 (en) 2014-02-20
AR082150A1 (es) 2012-11-14
US9102620B2 (en) 2015-08-11
WO2012006538A1 (en) 2012-01-12
EA201390081A1 (ru) 2013-07-30
IL251600A0 (en) 2017-06-29
NZ606587A (en) 2015-03-27
WO2012006538A8 (en) 2013-05-23
CL2013000063A1 (es) 2013-05-03
AU2011274496A1 (en) 2013-02-28
KR20130092558A (ko) 2013-08-20
US20140343096A1 (en) 2014-11-20
US8580819B2 (en) 2013-11-12
PH12013500065A1 (en) 2017-10-25
EP2597954A1 (en) 2013-06-05
PE20130396A1 (es) 2013-04-19
UY33504A (es) 2012-02-29
JP2017014238A (ja) 2017-01-19
CA2804986A1 (en) 2012-01-12
SG10201505236YA (en) 2015-08-28
BR112013000599A2 (pt) 2016-07-05
AU2011274496B2 (en) 2016-03-10
EP2597954A4 (en) 2014-01-01
SG186948A1 (en) 2013-02-28
CN104610144A (zh) 2015-05-13
US20120010238A1 (en) 2012-01-12
EP3213636A1 (en) 2017-09-06
JP2013535437A (ja) 2013-09-12
CN102984939A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
MX2013000333A (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
JP2021120420A (ja) ガンの治療方法
EP3348557B1 (en) Imidazo[1,2a]pyridines for treating or preventing hyperuricemia or gout
CN108366958A (zh) 用于治疗炎症相关病症的局部药物制剂
WO2013033688A1 (en) Treatment of cancer
Lödige et al. A primaquine–chloroquine hybrid with dual activity against Plasmodium liver and blood stages
JP2011529502A (ja) 抗マラリア化合物
JP2014534196A (ja) Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
TW201350467A (zh) Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
US20090137681A1 (en) Sirtuin Inhibiting Compounds
WO2008019292A2 (en) Compositions and methods for potentiating antibiotic activity
EP1435353A1 (en) Novel heterocyclic compound and anti-inflammatory agent
Bokosi et al. Synthesis, in silico docking studies, and antiplasmodial activity of hybrid molecules bearing 7‐substituted 4‐aminoquinoline moiety and cinnamic acid derivatives
Zhou et al. Antimicrobial activity, safety and pharmacokinetics evaluation of PMTM: A novel pleuromutilin candidate
US20130324598A1 (en) Treating mycobacterial infection with cu+/++ boosting therapeutics
WO2011091035A1 (en) Aminoquinoline derivatives
HK1236069A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CN112759549B (zh) 3-取代氨基-4-((取代吡啶基)氨基)环丁-3-烯-1,2-二酮类化合物
CN106581013B (zh) 一种水杨酸类化合物在制备神经退行性疾病药物中的用途
Espino‐Guarch et al. Ablation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting‐Induced Proteolysis
Appani et al. Design and Synthesis of Novel Triazoloquinazolin-5 (3 H)-one Analogues as Promising Antitubercular Agents
EP4446306A1 (en) Cannabidiol derivative, preparation method therefor and application thereof
Walczak et al. The Thermal Instability of 2, 4 and 2, 6‐N‐Alkylamino‐disubstituted and 2‐N‐Alkylamino‐substituted Nitrobenzenes in Weakly Alkaline Solution: sec‐Amino Effect
Mustafa et al. Synthesis of new metronidazole derivatives with suspected antimicrobial activity
WO2018076537A1 (zh) D-3-磷酸甘油酸脱氢酶别构抑制剂及其应用